期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

米诺环素对视网膜神经保护作用的研究进展 被引量：3

Research advances in retinal neuroprotective effects of minocycline
下载PDF
导出
摘要 米诺环素(minocycline)是一种第2代人工半合成的四环素类药,口服吸收好,脂溶性高,可穿透血-脑屏障,对人安全,已在中枢神经系统和视网膜疾病中表现出显著的神经保护作用。已知视网膜小胶质细胞在多种视网膜疾病中均有激活并参与病变发展,而米诺环素神经保护作用机制主要为抑制小胶质细胞和caspase-3激活。本文对米诺环素神经保护作用机制及在视网膜疾病中的保护作用做一综述。 Minocycline is a second-generation semisynthetic tetracycline. It has orally bioavailable, high liposolubility and a proven safety record in human, can cross the blood-brain barrier. It has predominant neuroprotective effect in many central nervous system and retinal diseases. In the retina, microglia become activated in various forms of retinal diseases. The primary mechanism of minocycline action is the inhibition of the activation of microglia and caspase-3. This article reviews the mechanism of neuroprotection by minocycline and neuroprotective effect in retinal disease.
作者 熊海波 刘苏
机构地区 重庆医科大学附属第二医院眼科
出处 《眼科新进展》 CAS 2007年第5期390-392,共3页 Recent Advances in Ophthalmology
关键词 米诺环素 凋亡 视网膜小胶质细胞 视网膜疾病 minocycline apoptosis retinal micro- glia cell retinal disease
分类号 R774.6 [医药卫生—眼科]
  • 相关文献

参考文献35

  • 1Zhu S,Stavrovskaya IG,Drozda M,Kim BY,Ona V,Li M,et al.Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice[J].Nature 2002 ;417 (6884):74-78.
  • 2Chen M,Ona VO,Li M,Ferrante RJ,Fink KB,Zhu S,et al.Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease[J].Nat Med 2000 ;6 (10):797-801.
  • 3Levkovitch-Verbin H,Kalev-Landoy M,Habot-Wilner Z,Melamed S.Minocycline delays death of retinal ganglion cells in experimental glaucoma and after optic nerve transection[J].Arch Ophthalmol 2006 ;124 (4):520-526.
  • 4Wang X,Zhu S,Drozda M,Zhang W,Stavrovskaya IG,Cattaneo E,et al.Minocycline inhibits caspase-independent and-dependent mitochondrial cell death pathways in models of huntington's disease[J].Proc Natl Acad Sci USA 2003; 100 (18):10483-10487.
  • 5Chen L,Yang P,Kijlstra A.Distribution,markers,and functions of retinal microglia.Ocular immunology and inflammation[J].Ocul Immunol Inflamm 2002;10(1):27-39.
  • 6Wang X,Tay SS,Ng YK.An immunohistochemical study of neuronal and glial cell reactions in retina of rats with experimental glaucoma[J].Exp Brain Res 2000; 132 (4):476-484.
  • 7Schuetz E,Thanos S.Microglia-targeted pharmacotherapy in retinal neurodegenerative diseases[J].Current Drug Targets 2004;5(7):619-627.
  • 8Kremlev SG,Roberts RL,Palmer C.Differential expression of chemokines and chemokine receptors during microglial activation and inhibition[J].J Neuroimmunol 2004; 149 (1-2):1-9.
  • 9Lai AY,Todd KG.Hypoxia-activated microglial mediators of neuronal survival are differentially regulated by tetracyclines[J].Glia 2006; 53 (8):809-816.
  • 10Si Q,Cosenza M,Kim MO,Zhao ML,Brownlee M,Goldstein H,et al.A novel action of minocycline:inhibition of human immunodeficiency virus type 1 infection in microglia[J].J Neurovirol 2004; 10 (5):284-292.

二级参考文献37

  • 1Ferrara N,Gerber HP,LeCouter J.The biology of VEGF and its receptors[J].Nat Med 2003; 9 (6):669-676.
  • 2Caldwell RB,Bartoli M,Behzadian MA,El-Remessy AE,AL-habrawey M,Platt DH.Vascular endothelial growth factor and diabetic retinopathy:pathophysiological mechanisms and treatment perspectives[J].Diabetes Metab Res Rev 2003;19 (6):442-455.
  • 3Gilbert RE,Vranes D,Berka JL,Kelly DJ,Cox A,Wu LL,et al.Vascular endothelial growth factor and its receptors in control and diabetic rat eyes[J].Lab Invest 1998; 78(8):1017-1027.
  • 4Funatsu H,Yamashita H,Nakanishi Y,Hori S.Angiotensin Ⅱ and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy[J].Br J Ophthalmol 2002;86(3):311-315.
  • 5Tolentino MJ,McLeod DS,Taomoto M,Otsuji T,Adamis AP,Lutty GA.Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate[J].Am J Ophthalmol 2002; 133(3):373-385.
  • 6Okamoto T,Yamagishi S,Inagaki Y,Amano S,Koga K,Abe R,et al.Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin[J].FASEB J 2002; 16(14):1928-1930.
  • 7Hogeboom van Buggenum IM,Polak BC,Reichert-Thoen JW,de Vries-Knoppert WA,van Hinsbergh VW,Tangelder GJ.Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy[J].Diabetologia 2002;45 (2):203-209.
  • 8Zhang X,Lassila M,Cooper ME,Cao Z.Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors[J].Hypertension 2004;43(2):276-281.
  • 9Obrosova IG,Minchenko AG,Marinescu V,Fathallah L,Kennedy A,Stockert CM,et al.Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats[J].Diabetologia 2001 ;44(9):1102-1110.
  • 10Obrosova IG,Minchenko AG,Vasupuram R,White L,Abatan OI,Kumagai AK,et al.Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats[J].Diabetes 2003; 52 (3):864-871.

共引文献11

同被引文献50

引证文献3

二级引证文献5

眼科新进展
2007年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部